148 related articles for article (PubMed ID: 10524648)
1. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis.
Jones EA; ten Kate FJ; ter Borg F; Houben M; Reesink HW; Chamuleau RA
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1165-9. PubMed ID: 10524648
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Talwalkar JA; Angulo P; Keach JC; Petz JL; Jorgensen RA; Lindor KD
J Clin Gastroenterol; 2005 Feb; 39(2):168-71. PubMed ID: 15681915
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil for primary biliary cirrhosis--convergent thinking.
Altschuler EL
Eur J Gastroenterol Hepatol; 2000 May; 12(5):587. PubMed ID: 10833107
[No Abstract] [Full Text] [Related]
5. Triple therapy for patients with primary biliary cirrhosis with progressive disease despite ursodeoxycholic acid: another step forward.
Kaplan MM; Bonis PA
Gastroenterol Clin Biol; 2010; 34(4-5):239-41. PubMed ID: 20462715
[No Abstract] [Full Text] [Related]
6. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Treiber G; Malfertheiner P
J Clin Gastroenterol; 2005 Oct; 39(9):837-8; author reply 838. PubMed ID: 16145353
[No Abstract] [Full Text] [Related]
7. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid.
Kaplan MM; Bonder A; Ruthazer R; Bonis PA
Dig Dis Sci; 2010 Nov; 55(11):3207-17. PubMed ID: 20559727
[TBL] [Abstract][Full Text] [Related]
9. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
10. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
11. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
Silveira MG; Lindor KD
Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
16. Post-liver transplantation de novo hepatitis with overlap features.
Keaveny AP; Gordon FD; Khettry U
Pathol Int; 2005 Oct; 55(10):660-4. PubMed ID: 16185298
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.
Fan X; Zhu Y; Men R; Wen M; Shen Y; Lu C; Yang L
Can J Gastroenterol Hepatol; 2018; 2018():1965492. PubMed ID: 30155449
[TBL] [Abstract][Full Text] [Related]
18. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.
Kuiper EM; Hansen BE; Lesterhuis W; Robijn RJ; Thijs JC; Engels LG; Koek GH; Aparicio MN; Kerbert-Dreteler MJ; van Buuren HR;
Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):29-33. PubMed ID: 20810227
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
[TBL] [Abstract][Full Text] [Related]
20. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
